Century Therapeutics, Inc. (IPSC)
Company Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.
The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma.
Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 18, 2021 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 170 |
Contact Details
Address: 3675 Market Street Philadelphia, PA 19104 United States | |
| Phone | 267 817 5790 |
Stock Details
| Ticker Symbol | IPSC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $20.00 |
| CIK Code | 1850119 |
Key Executives
| Name | Position |
|---|---|
| Dr. Osvaldo Flores Ph.D. | President, Chief Executive Officer and Director |
| Dr. Adrienne Farid Ph.D. | Chief Operations Officer |
| Dr. Luis Borges | Chief Scientific Officer |
| Douglas Carr CPA | Vice President of Finance and Operations and Secretary |
| Dr. Gregory Russotti Ph.D. | Chief Technology Officer |
| Kenneth J. Dow J.D. | Head of Legal and Compliance |
| Dr. Shane Williams Ph.D. | Chief People Officer |
| Dr. Michael C. Diem | Chief Business Officer |
| Dr. Hyam I. Levitsky M.D. | President of Research & Development |
| Mark Wallet | Head of Immunology and Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 10, 2022 | 8-K | Current report |
| Apr 21, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2022 | DEF 14A | Other definitive proxy statements |
| Apr 13, 2022 | 8-K | Current report |
| Mar 17, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 17, 2022 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Mar 17, 2022 | 8-K | Current report |
| Feb 11, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 11, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 10, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| View All SEC Filings | ||